(Q36739272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

The cardiovascular effects of selective estrogen receptor modulators (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Christodoulakos GE

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Botsis DC

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

English

0 references

publication date

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

25 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

1092

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

374-384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17308162%20AND%20SRC:MED&resulttype=core&format=json

Menopause and heart disease. A review

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Hormone replacement therapy, heart disease, and other considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Selective oestrogen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Coregulator function: a key to understanding tissue specificity of selective receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Influence of age and menopause on serum lipids and lipoproteins in healthy women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

The protective effects of estrogen on the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Biology: risk factor modification by OCs and HRT lipids and lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Primary and subsequent coronary risk appraisal: new results from the Framingham study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Rise and fall of hormone therapy in postmenopausal women with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Estrogen and homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Increased plasma homocysteine after menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Menopause, the cardiovascular risk factor homocysteine, and the effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Do estrogen effects on blood vessels translate into clinically significant atheroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Chemokines and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Endothelial function and menopause: effects of raloxifene administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1365.034